Esperante Ventures

Esperante Ventures

Esperante Ventures is a Netherlands based venture capital firm focused on investing in life sciences companies.

Esperante Ventures is a Hoofddorp, Netherlands based venture capital firm. They focus on investing in life sciences companies, specifically in drug development, diagnostic and bio-marker tests and pharmaceutical sales.

Esperante Ventures invests between €300,000 to €700,000 for an equity stake of 3% to 33%. They look to deliver for their investments to have management ready to bring the company to financial independence or a liquidity event or exit within five years.

Founded in 2004 as a private investment company, Esperante Ventures is controlled by C&P Group Holdings, a privately controlled life sciences interest group.

Investment

Esperante Ventures has made investments in Versantis, Arquer Diagnostics, Oxford Cancer Biomarkers, Cytox, Haemostatix, Anergis, Canbex Therapeutics, Karus Therapeutics, Novacta Biosystems and Cara Therapeutics.

Esperante Ventures exited their investments in Haemostatix, Canbex Therapeutics, Thiakis, Pinnacle Biologics and Cara Therapeutics.

Timeline

Funded Companies

Company
Description
Industry
Website
Location
Oxford Cancer Biomarkers

Oxford Cancer Biomarkers is an Oxford-based biomarker company commercializing biomarker tests for colorectal cancer testing.

Versantis is a Switzerland-based company.

2 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Dean Slagel

Managing Director

Erik Schropp

Director

Sandy Primrose, PhD, MBE

Advisor

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.